Table 2.

Clinical outcomes of the cohort

Clinical outcomes	All patients (n = 106)	60 mg (n = 51)	80 mg (n = 55)
Treatment outcomes; n (%)
Partial response	90 (84.9%)	41 (80.4%)	49 (89.1%)
Stable disease	13 (12.3%)	8 (15.7%)	5 (9.1%)
Progressive disease	2 (1.9%)	2 (3.9%)	0
Unknown	1 (0.9%)	0	1 (1.8%)
Objective response rate; % (95% CI)	84.9% (76.6%, 91.1%)	80.4% (66.9%, 90.2%)	89.1% (77.8%, 95.9%)
Disease control rate; % (95% CI)	97.2% (92.0%, 99.4%)	96.1% (86.5%, 99.5%)	98.2% (90.3%, 100.0%)
Survival outcomes; median (95% CI)
Median PFS (months)	15.4 (12.9, 17.9)	15.1 (11.7, 18.5)	15.4 (10.5, 20.3)
Median OS (months)	31.6 (26.4, 36.8)	30.6 (24.0, 37.2)	32.1 (27.0, 37.2)

CI confidence intervals, PFS progression-free survival, OS overall survival